Remove Information Remove Labelling Remove Medication Labelling
article thumbnail

Drug Storage

RX Note

Introduction Once, I received a query from a ward nurse: If a product label mentioned that "Do not store over 25°C", is it fine for us to keep the medication in fridge? What does a cool place on the product label mean? Read the label to know the recommended storage temperature range.

article thumbnail

LENZ Therapeutics’ Presbyopia Treatment VIZZ Receives FDA Approval in the U.S.

PharmExec

August 1st 2025 FDA Mandates Safety Alterations to Opioid Pain Medication Labels Nicholas Jacobus FDA mandates new opioid labeling to highlight long-term risks, aiming to combat addiction and improve patient safety in pain management.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA Mandates Major Opioid Label Revisions to Highlight Long-Term Risks

Pharmacy Times

Labels now emphasize the risks of higher doses and caution against abrupt discontinuation in dependent patients to prevent withdrawal and other harms. SHOW MORE The FDA intends to update opioid labels to highlight risks of addiction, overdose, and interactions, enhancing safety in pain management practices.

article thumbnail

FDA Mandates Safety Alterations to Opioid Pain Medication Labels

PharmExec

New labels will include study summaries, improved dosage warnings, and information on overdose reversal agents to enhance patient and healthcare professional awareness. Label changes aim to promote safer, research-supported decision-making, with a 30-day window for industry recipients to submit updates for review.

article thumbnail

FDA Changes Opioid Pain Medication Labeling Requirements

PharmaTech

Required labeling updates include clearer risk information, stronger warnings, and guidance on opioid use, with a 30-day submission deadline for manufacturers. SHOW MORE The changes, required for safety labeling of all opioid drugs, will emphasize the risks with long-term use to combat misuse and addiction.

article thumbnail

FDA Grants Accelerated Approval to Jazz Pharmaceuticals’ Modeyso for H3 K27M-Mutant Diffuse Midline Glioma

PharmExec

" Phase II Efficacy and Safety Data The efficacy and safety of Modeyso were evaluated across five open-label, non-randomized Phase II trials: ONC006, ONC013, ONC014, ONC016, and ONC018. Gliomas are considered the most common tumors of the central nervous system, representing 25% of all tumors diagnosed in the United States annually.

article thumbnail

Pharma Industry Execs React to President Trump’s 60-Day MFN Deadline

PharmExec

Related Videos Related Content Advertisement August 1st 2025 FDA Mandates Safety Alterations to Opioid Pain Medication Labels Nicholas Jacobus FDA mandates new opioid labeling to highlight long-term risks, aiming to combat addiction and improve patient safety in pain management. Subscribe Now!